BLOOD TRANSFUSION.ppt

lecture

1. Guidelines for
Blood Transfusion Practice
By
Dr . Magdy Shafik Ramadan
Senior Pediatric and Neonatology consultant
M.S, Diploma, Ph.D of Pediatrics

2. •Blood transfusion is an important part of
day‐to‐day clinical practice.
•Blood and blood products provide unique
and life‐saving therapeutic benefits to
patients.
•Nursing staff plays a very important role and
crucial role in the blood transfusion
procedure

3. outlines
•1-History
•2-purpose
•3-blood and blood component
•4 –guidelines for use of blood and blood
component
•5- مدلا لفن تاوطخ
•6-Other aspects of transfusion
•7-Transfusion Therapy in Special Conditions
•8-Transfusion reaction

4. History
•in 1915, Richard Lewison l in New York
City initiated the use of sodium citrate as an
anticoagulant.
•• This discovery transformed the blood
transfusion procedure from direct (vein-to-
vein) to indirect.
•• In the same year, Richard Weil
demonstrated the feasibility of refrigerated
storage of anticoagulated blood

5. •The introduction of a citrate-glucose
solutionby Francis Peyton Rous and JR
Turner two years later permitted storage of
blood in containers for several days, thus
opening the way for the first "blood depot"
established in Britain during World War I.
•-1930s, the Soviet Union had set up a system
of at least sixty large blood centers and
more than 500 subsidiary ones, all storing
"canned" blood and shipping it to all
corners of the country.

6. •• News of the Soviet experience traveled to
America, where in 1937 Bernard Fantus,
director of therapeutics at the Cook County
Hospital in Chicago, established the first
hospital blood bank in the United States.
••Within a few years, hospital and community
blood banks were established across the
United States.

7. •• Willem Johan Kolff organized the first
blood bank in Europe (in 1940).
•• An important breakthrough came in 1939-
40when Karl Landsteiner, Alex Wiener,
Philip Levine, and R.E. Stetson discovered
the Rh blood group system, which was
found to be the cause of the majority of
transfusion reactions up to that time.

8. •Three years later, the introduction acid-
citrate-dextrose (ACD) solution, which
reduces the volume of anticoagulant,
permitted transfusions of greater volumes
of blood and allowed longer term storage.
•• Carl Walter and W.P. Murphy, Jr.,
introduced the plastic bag for blood
collection in 1950.

9. •Replacing breakable glass bottles with
durable plastic bags allowed for the
evolution of a collection system capable of
safe and easy preparation of multiple blood
components from a single unit of Whole
Blood.
•• An anticoagulant preservative, CPDA-1
was introduced in 1979. It decreased
wastage from expiration and facilitated
resource sharing among blood banks.
Newer solutions contain adenine and extend
the shelf life of red cells to 42 days.

10. • Clinical Transfusion Practice
• Guidelines for Medical Interns
•

11. Purpose
•Restore blood volume
•Replace clotting factors
•Improve oxygen carrying capacity
•Restore blood elements that are
depleted
•Prevent complications
•To raise the haemoglobin level
•To provide antibodies

12. •3-blood and blood
component

13. •
Blood Components
•A blood component is a constituent of blood,
separated from whole blood, such as:
•Red cell concentrate
•Plasma
•Platelet concentrate
•Cryoprecipitate, prepared from fresh
frozen plasma; rich in Factor VIII and
fibrinogen

15. •A plasma derivative is made from human
plasma proteins prepared under
pharmaceutical manufacturing conditions,
such as:
•Albumin
•Coagulation factor concentrates
•Immunoglobulin

16. •1-Whole blood
•Description:
•450 mL whole blood in 63 mL
anticoagulant‐preservative solution of which Hb
will be approximately 1.2 g/dL and haematocrit
(Hct) 35‐45%.
•Storage:
•Between +2°C and +6°C in an approved blood
bank refrigerator, fitted with a temperature
monitor and alarm.
•Indications:
•Red cell replacement in acute blood loss with
hypovolaemia.
•Exchange transfusion.

17. Contraindications:
Risk of volume overload in patients with:
Chronic anemia.
Incipient cardiac failure.
•2-packed red blood cells (PRBC
•Description:
•150‐200 mL red blood cells from which most of the
plasma has been removed. Hbconcentration will be
approximately 20 g/100 mL (not less than 45 g per
unit) and Hct55‐75%.

18. •Indications:
•Replacement of red cells in anemic patients.
•1 unit of PRBCs = raises hematocrit by 2-3%
•3-Platelet concentrates (PC)
•Description:
•A single donor unit consists of 50‐60 mL plasma
that should contain ≥55 x 109 platelets.
•Storage:
•PCs may be stored for up to 5 days at +20°C to
+24°C (with agitation). PCs require continuous
agitation
•during storage, on a platelet shakerand in an
incubator that maintains the required storage
temperature.

19. •Dosage:
•1 unit of platelet concentrate/10 kg;
•for an adult of 60‐70 kg, 4‐6 single donor units containing
at least 240 x 109 platelets should raise the platelet count
by 20‐40 x 109/L. Increment will be less if there is
splenomegaly, disseminated intravascular coagulation
(DIC) or septicaemia.
•Indications:
•Treatment of bleeding due to:
•Thrombocytopenia.
•Platelet function defects.
•Prevention of bleeding due to thrombocytopenia as in
bone marrow failure

20. •Administration:
•should be infused as soon as possible because of
the risk of bacterial proliferation.
•a unit should be infused over a period of not more
than 30 minutes.
•Do not give plateletconcentrates prepared from
RhDpositive donors to an RhDnegative female
with childbearing potential.
•Give platelet concentrates that are ABO
compatible, whenever possible

21. 4-Fresh Frozen Plasma (FFP)
•Unit of issue:
200‐300 mL.
•Storage:
•FFP is stored at –25°C or colder forup to 1
year. Before use, it should be thawed in the blood
transfusion centrebetween +30°C and +37°C.
•Dosage: 15 mL/kg.
•Administration:
•Should be ABO compatible.
•Infuse as soon as possible after thawing.
•Labile coagulation factors rapidly degrade; use
within 6 hours of thawing.
•

22. •FFP may be beneficial if PT and/or partial
thromboplastin time (PTT) >1.5 times normal.
•1 unit of FFP = increases level of any clotting
factor by 2-3%
•5-Cryoprecipitated anti‐haemophilicfactor
(Cryo‐AHF)
•Description:
•Cryo‐AHF is prepared from FFP by collecting the
precipitate formed during controlled thawing at
+4°C and re‐suspending in 10‐20 mL plasma.It is
stored at –25°C or colder for up to 1 yearafter the
date of phlebotomy.

23. •Cryo‐AHF containsabout half the Factor VIII
and fibrinogen as a pack of fresh whole blood:
e.g. Factor VIII: 80‐100 iu/ pack; fibrinogen:
150‐300 mg/ pack.
•Administration:
•ABO compatible product should be used.
•After thawing, infuse as soon as possible.
•Must be transfused within 6 hours of thawing

24. مدلا لقن ةيلمع يف ضيرمتلا رود
1-اذملو اهيريضحت بولطملا هتاقتشمو مدلا ةيعون ةفرعم1
2- اهئاطعا ةدمو ةبولطملا ةيمكلا ةفرعم
3- ضيرملا جايتحا يدم ةفرعم(لا ما لجاع)
4- مدلا ريضحت بلط ةباتك
5-ةنيعلا بحس
6- قفاوتلا لمعل مدلا كنبل اهلاسرا
7- بولطملا سيكلا ملاتسا
8-هتاقتشم وا مدلا لقن ةيلمعل ةمزلالا تاطايتحلاا ةفرعم
9- مدلا لقن ءانثا ةبولطملا تاظحلاملا ةفرعم
10- بحاصت يتلا ةيبناجلا ضارعلاا عم لماعتلا ةيفيك ةفرعم
مدلا

25. 1-اهيريضحت بولطملا هتاقتشمو مدلا ةيعون ةفرعم
•ءارمحلا مدلا تارك لقن:
ةنمزم وا ةداح ريسكت ايمينا داحلا فيزنلا
ماظعلا عاخن رومض ايمنا1
ةيومدلا حئافصلا لقن :1
ةيومدلا حئافصلا فئاظو وا ددع يف صقن
امزلابلا لقن
لماعك ةيثارولا طلجتلا لماوع يف صقن8 و9

26. 2-اهئاطعا ةدمو ةبولطملا ةيمكلا ةفرعم
•ءارمحلا مدلا تارك لقن:
• 10-20ml/kg
• نع ديزتلا ةدم يف يطعت4 تاعاس
ةجلاثلا نم اهجورخ نم ةعاس فصن للاخ يف يطعت
ةيومدلا حئافصلا لقن :1
يطعتةعاس فصن نع لقت ةدم يف ةرشابم
امزلابلا لقن
ةرارح ةجرد يف ظفحت نا نكميو نابوذلا دعب ةرشابم يطعت6
للاخ يف مدختستل4 تاعاس . نم ةدم يف يطعتو1-2ةعاس

27. - ضيرملا جايتحا يدم ةفرعم(لا ما لجاع)
• ةلجاع ريغلا تلااحلاو لاحلا يف رضحت ةلجاعلا تلااحلا
للاخ يف ريضحتلاب حمسي24 ةعاس
4- مدلا ريضحت بلط ةباتك
• يثلاث مسلااك ضيرملل ةلماك تانايب يلع يوتحي نا بجي
لوئسملا بيبطلا عيقوت كلذكو همد ةليصفو ضيرملا مقرو.
5-ةنيعلا بحس
• هتقباطمو ةنيعلا يلع حوضوب همقرو ضيرملا مسا ةباتك
قباسلا ريضحتلا بلط يف بوتكملل

28. ةنيعلا لاسرا
مسا ةفرعمو اهنم دكأتلاو قباطتلا ةيلمع ءارجاو مدلا كنب يلا
لمعلاب مئاقلا
• 7- بولطملا سيكلا ملاتسا
نوللاب ريغت يا ةظحلام
سيكلاب بيرست يا ةظحلام
سيكلاب تاطلج يا دوجو
مدلا ةليصفو سيكلا يلع ةبوتكملا ةيحلاصلا خيرات ةظحلام
عربتملا مساو

29. 1- اديج نيديلا لسغ
2-لاويناكلا مجح بساني مدلا لقنل ريبك ديرو نع ثحبلا
3- مدلا لقن لبق ضيرملل ةيويحلا تاملاعلا
4- مدلا ةئفدت
5- نم هجورخ نم ةعاس فصن للاخ يف مدلا ءاطعا
ةجلاثلا
لقنلا ةيلمع يف مدلا حشرم وا رتلف مادختسا
مدلا لقن عم ئش يا ةفاضا مدع
8
- مدلا لقن ةيلمعل ةمزلالا تاطايتحلاا ةفرعم وا
هتاقتشم

30. 9-مدلا لقن ءانثا ةبولطملا تاظحلاملا ةفرعم
لوا15ةقيقد
•هجولاب رارمحا ثودح
•ةكح
•ءيق
•ةرارحلا ةجرد يف عافترا
•ضبنلا يف ةدايز
• عادص
• لوبلا نول ريغت
• ةشعر وا رهظلاب ملاا

31. 10- مدلا بحاصت يتلا ةيبناجلا ضارعلاا عم لماعتلا ةيفيك ةفرعم
• سناجتلا مدع بسب مدلا ريسكت تلااح
•ةيرارحلا تلاعافتلا تلااح
•ةيساسحلا تلاعافتلا تلااح

32. سناجتلا مدع بسب مدلا ريسكت تلااح
•و هجولاب رارمحا ثودح
• ةرارحلا ةجرد يف عافترا- وا ردصلاو نطبلا يف ملا
ضبنلا يف ةدايز- لوبلا نول ريغت و طعضلاب ضافخنا
• لوقنملا مدلا نايرس ناكم يف ملا
•ةضرمملا نم ءارجلاا:
• تا بجيحلم لولحم لقنيو مدلا لقن فقوي
• ةرشابم بيبطلا غلبي

33. • تانايبلا هذه ليصفتلاب بتكت نا ةضرمملا يلع:
•هتياهتو مدلا لقن ةيادب
• سيكلا يلع امك مدلا ريضحت نع لوئسملا مسا
• مدلا لقن نع ضرمملا لوئسملا مسا
•مدلا لقن دعب ضيرملا ةلاح
• لباقملا ديرولا نم ضيرملا نم مد ةنيع بحست عم لسريو
مدلا كنب يف ةيناث ةقباطملا لمعل سيكلا .
•

34. ةيرارحلا تلاعافتلا تلااح
• يف ثدحت20 %
• مدلا لقن ةياهن يف رهظت
• جلاعلا :ةرارحلا تاداضم
• مدلا لقن ةعرس ليلقت
•مدلا لقن يف رتلفلا مادختسا

35. ةيساسحلا تلاعافتلا تلااح
• قئاقد للاخ يف ةكحو دلجلا يلع حفط ةروص يف رهظت
مدلا لقن نم .
• جلاعلا : ةيساسحلا تاداضم
•مدلا لقن ةعرس ليلقت

36. •4 –guidelines for use of
blood and blood
component

37. Guidelines for blood transfusion
Indications
NB: Hbshould not be the sole deciding factor for
transfusion.
Haemoglobin(Hb)
trigger for
transfusion
•If there are signs or symptoms of impaired oxygen transport
•Lower thresholdsmay be acceptable in patients without symptoms
and/or where specific therapy is available e.g. sickle cell disease or
iron deficiency anemia
< 7 g/dL
•Preoperative and for surgery associated with major blood loss. < 7 –8 g/dL
•In a patient on chronic transfusion regimen or during marrow
suppressive therapy.
< 9 g/dL
•Not likely to be appropriate unless there are specific indications.
Acute bloodloss >30-40% of total blood volume.
< 10 g/dL

38. Guidelines for blood component therapy
Indications
Platelet Count
trigger for
transfusion
As prophylaxis in bone marrow failure. < 10 x 109 /L
Bone marrow failure in presence of additional risk factors:
fever, antibiotics, evidence of systemic haemostaticfailure
< 20 x 109 /L
In patients undergoing surgery or invasive procedures.
•Diffuse microvascularbleeding-DIC
< 50 x 109 /L
•Brain or eye surgery.
Any BleedingPatient
•Appropriate when thrombocytopenia is considered a
major contributory factor.
< 100 x 109 /L
•In inherited or acquired qualitative plateletefunction
disorders, depending on clinical features & setting.
Any platelet count

39. Guidelines for blood component transfusion
Indications
•Multiple coagulationdeficiencies associated with acute DIC.
•Inherited deficiencies of coagulation inhibitors in patients
undergoing high-risk procedures where a specific factor
concentrate is unavailable.
•Thrombotic thrombocytopenia purpura(plasma exchange is
preferred)
•Replacement of single factor deficiencies where a specific or
combined factor concentrates is unavailable. •Immediate
reversal of warfarin effect in the presence or potentially life-
threatening bleeding when used in addition to Vitamin K & /
or Factor Concentrate (Prothrombinconcentrate)
•The presence of bleeding and abnormal coagulation
parameters following massive transfusion or cardiac bypass
surgery or in patients with liver disease deficiency.
FFP trigger for
transfusion
Indications
PT& PTT are
more than 1.5
times the upper
limit of normal
range
Fibrinogen< 1gm/L •Congenital or acquired fibrinogen
deficiency including DIC. •Hemophilia A, von
Willebranddisease (if the concentrate is not available).
•Factor XIII
Cryoprecipitate
trigger for
transfusion

40. Preparation for Transfusion
•Take a blood sample for cross match for red and
white blood cell products.
•►Send a minimum of 2 ml in an EDTA
•►Specimens are appropriate for only 72 hrs.

41. مدلا لقن تاوطخ
• هتاقتشم وأ مدلا لقن متي بوتكم رمأببيبطلا نم .
• ذخأ بجي لهلأا ةقفاوم،هتاقتشم وأ مدلا لقن ءارجإ ىلع دعب
ءارجلإا اذھ لثمل ءوجللا ببس حرش .
•اًينيتور يديلأا لسغُتلالا تاودلأا ريضحت متيو ، لقنل ةمز
مدلا .
• نم دكأتلاديلولا مسا .
• ةضرمملاو بيبطلا ىلع بجي مسا دوجو نم اًعم دكأتلا
مث ،مدلا سيك ىلع سوزير لماعمو ،مدلا ةليصف ،ديلولا
•لئاصفلا قفاوت رابتخا لمع ةباتك نم اًضيأ دكأتلا ،

42. • نم دكأتلاةبولطملا مدلا ةيمك .
• نم دكأتلامدلا سيك ىلع نودملا مدلا ةيحلاص خيرات .
• نم دكاتلامدلاب تاطلجت دوجو مدع.
• ةظحلام ةيويحلا فئاظولااهنيودتو ،ديلولل
•ديلولل هلقن لبق مدلا ةئفدت ،يف ةيفاك ةدمل اهكرتب ةجرد
ةفرغلا ةرارح .ضوب سيكلا ةئفدت اًتاب اًعنم عنمُيو تحت اهع
ريسكت متي لا ىتح ،يرارح ردصم يأ وأ نخاسلا ءاملا
ءارمحلا مدلا تايرك.
• ىلع مدلا رمي نأ بجي حشرم(رتلف )مدلاب صاخ

43. • حشرم ىلع مدلا رمي نأ بجي(رتلف )مدلاب صاخ
•مدلا تارك لقنل ةيكيناكيم ةخضم يأ مادختسا بجي لاو
اھريسكت متي لا ىتح ،ءارمحلا.
• ليصوت ةيئرملا ةبقارملا زاهج ىلع ديلولا(روتينوم)

45. •The blood unit must be discarded if:
•It has been out of the refrigerator for longer
than 30 minutes, or
•The seal is broken, or
•There is any sign of haemolysis, clotting or
contamination

46. Duration times for transfusion
•Complete
transfusion
•Start transfusion•Blood products
•≤ 4 hours
•Discard unit if this
period is exceeded
•Within 30 minutes
of
•removing from
refrigerator
•Whole blood /
PRBC
•Within 30 minutes•Immediately•Platelet concentrate
•Within 30 minutes•As soon as possible•FFP
•Within 30 minutes•As soon as possible•Cryoprecipitate

47. •6-Other aspects of
transfusion

48. Other aspects of transfusion
•1 -Warming blood
•2 -Use of medication at time
of transfusion
•3-Use of fresh blood

49. 1 -Warming blood
•Warmed blood is most commonly required
in:
•Large volume rapid transfusions:
-Adults: more than 50 mL/kg/hour.
-Children: more than 15 mL/kg/hour
•Exchange transfusion in infants
•Patients with clinically significant cold
agglutinins.

50. •Blood should only be warmed in a blood
warmer.
•Blood should never be warmed in a bowl of
hot wateras this could lead to hemolysis of
the red cells which could be life‐threatening
when transfused.

51. Use of medication at time of transfusion
•It is generally not recommended to routinely use
pre‐medication like anti‐histamines, steroids
•or other medication before transfusion.
•This practice may mask or delay the signs and
•symptoms of an acute transfusion reaction.

52. Addition of medicine or other fluids with
blood and blood components
•Medicines or other fluids should never be infused
within the same line as blood and blood
components.
•The exception is normal saline (sodium chloride
0.9%) which may be used in special
circumstances, e.g. when the flow is slow due to
increased Hct.
•Use a separate IV line if an intravenous fluid has
to be given at the same time as blood transfusion.

53. Use of fresh blood
•Stored blood less than 7 days old is termed “fresh
blood
•Uses ( to avoid biochemical overload) to raise Hb:
-Renal and liver dysfunction.
-Patient requiring massive blood transfusion.
-Patient with raised plasma potassium due to extensive
burns, or intravascular haemolysis.
-Neonaterequiring exchange transfusion

54. Transfusion Therapy in
Special Conditions

55. •Emergency transfusion
•Massive blood transfusion
•Transfusion in pediatric

56. •Emergency Transfusion
•• Group O–negative RBC units should be used,
especially if the patient is a female of childbearing
period.
•A male patient or an older female patient can be
switched from Rh-negative to Rh-positive RBCs if
fewO-negative units are available and massive
transfusion is required.

57. Massive Blood Transfusion
•Massive blood transfusion may be defined as the
replacement of one blood volume (equivalent to 10
units of blood) in any 24 hour period,
•or half of the blood volume (5 units of blood) in
any four hour period in an adult.
•or Transfusion >4 units in 1 hour.

58. •Massive transfusion occurs in:
--severe trauma,
-ruptured aortic aneurysm,
-surgery
-obstetric complications.

59. •Mortalityis highin massive transfusion and its
aetiologyis multifactorial
•hypotension, acidosis, coagulopathy, shock
•administering large volumes of blood and
intravenous fluids may itself give rise to the
following complications:
•Acidosis
•Hyperkalaemia
•Citrate toxicity and hypocalcaemia

60. Acidosis
•Acidosis in a patient receiving a large volume
transfusion is more likely to be the result of
inadequate treatment of hypovolaemiathan due
to the effects of transfusion.
•Under normal circumstances, the body can readily
neutralize this acid load from transfusion.

61. Hyperkalaemia
•The storage of blood results in a small increase in
extra‐cellular potassium concentration
•increase the longer it is stored.
•This rise is rarely of clinical significance, other
than in neonatal exchange transfusions.

62. Citrate toxicity and hypocalcaemia
•Hypocalcaemia, particularly in combination with
hypothermia and acidosis, can cause a reduction
in cardiac output, bradycardia, and other
dysrhythmias.
•It is therefore unnecessary to attempt to neutralize
the acid load of transfusion.

63. •Management
If there is prolongation of PT, give ABO
compatible fresh frozen plasma in a dose of 15
mL/kg
If the APTT is also prolonged, Factor
VIII/fibrinogen concentrate is recommended in
addition to FFP.
If none is available, give 10‐15 units of ABO
compatible cryoprecipitate, which contains
Factor VIII and fibrinogen.

64. •Consider PC (platelets concentrates)transfusion
in cases where the platelet count falls below 20 x
109/L, even if there is no clinical evidence of
bleeding.
•The prophylactic useof platelet concentrates in
patients receiving large volume blood transfusions
is not recommended.

65. Transfusion in Pediatrics
•Transfusion of Neonates and Infants:
Pre‐transfusion testing:
•Maternal samples:
• ABO and RhDgroup
• Antibody screen (5 mL clotted blood)
•Infant samples:
•ABO and RhDgroup
•Direct antiglobulin test (DAT)
•Antibody screen if maternal sample unavailable

66. •If the maternal antibody screen is negative and the
infant’s red cells are DAT negative, cross
matching is unnecessary and blood of the baby’s
group can be issued.
•If the maternal antibody screen and/or the
neonatal DAT are positive, serological
investigation and full compatibility testing will be
necessary .
•After the first four months of life, cross matching
procedures should conform to the requirements
•for older children/adults.
•.

67. Neonatal Platelets Transfusion
•stable healthy term infant with a platelet count as low
as 20,000-30,000/μLmay be allowed a platelet
transfusion.
•Prophylactic platelet transfusions should be
considered for ill neonates with platelet count less
than 20,000-50,000/μL.
•Infants receiving indomethacinor
thrombolytics/anticoagulants should have a platelet
count of more than 75,000/μL.

68. •Platelets are administered in 10 ml/kg aliquots/hr.
•Infants receive type specific or group O platelets
in plasma compatible with the infant.
•1 unit = increases the average adult client’s
platelet count by about 5,000 platelets/microliter

69. •Transfusion Reaction

71. Transfusion reaction (TR)
•Acute TR (<24 hours)
-Wrong blood, primed immunological recipient
-Poor quality blood, faulty assessment
•Delayed TR (>24 hours)
-Diseases, other delayed immunologic reactions,
metabolic effect (5‐10 days)

72. Guidelines for recognition and
management of acute transfusion
reactions
•Category 1: Mild reactions
Possible causeSymptomsSigns
HypersensitivityPruritusUrticaria
Rash

73. •Immediate management of Category 1:
Mild reactions
•Slow the transfusion.
•Administer antihistamine IM.
•If no clinical improvement within 30
minutes or if signs and symptoms worsen,
treat as Category 2 .
•If improved, restart transfusion slowly.

74. Category 2: Moderately severe reactions
Possible causeSymptomsSigns
HypersensitivityAnxiety
Pruritus
Palpitations
Mild dyspnea
Headache
Flushing
Urticaria
Rigors
Fever
Restlessness
Tachycardia

75. •Immediate managementof Category 2:
Moderately severe reactions
•1-Stopthe transfusion and keep IV line open with
normal saline in another site.
•2-Return the blood unit with transfusion
administration set, freshly collected urine and new
blood samples (1 clotted and 1 anticoagulated),
drawn from a vein opposite to the transfusion site,
to the blood transfusion center for laboratory
investigations.

76. •3-Administer antihistamine IM and oral or rectal
antipyretic.
•4-Give IV corticosteroids and bronchodilatorsif
there are anaphylactoid features
•5-If clinical improvementoccurs, restart
transfusion slowly with new blood unit.
•6-If no clinical improvement within 15 minutes or
if signs and symptoms worsen, treat as Category 3.
•7-Collect urine for next 24 hours for evidence of
haemolysisand send for laboratory investigations.
•8-If available, a leucocyte reduction filter (WBC
filter) may be used in repeated transfusion

77. Category 3: Life‐threatening reactions
Possible causeSymptomsSigns
Acute intravascular
haemolysis
(mismatched blood
transfusion)
Bacterial
contamination and
septic shock
Fluid overload
Anaphylaxis
Transfusion related
acute lung
injury (TRALI
Anxiety
Chest pain
Pain along the
transfusion line
Respiratory
distress/shortness
of breath
Loin/back pain
Headache
Dyspnoea
Rigor
Fever
Restlessness
Hypotension(fall of
20% in
systolic BP)
Tachycardia(rise of
20% in
heart rate)
Haemoglobinuria(Hb
in urine)
Unexplained
bleeding (DIC)

78. Immediate management of Category 3:
Life‐threatening reactions
•Stop the transfusion and keep IV line open with
normal salinein another site.
•Infuse normal saline to maintain systolic BP.
•Maintain airway and give high flow oxygen by
mask.
•Give adrenaline (as 1:1000 solution) 0.01 mg/kg
body weight by slow intramuscular injection.
•Give IV corticosteroids and bronchodilators if
there are anaphylactoid features

79. •Give diuretic: e.g. frusemide 1 mg/kg IV or
equivalent.
•Check a fresh urine specimen visually for signs
of haemoglobinuria.
•Send blood unit with transfusion set, fresh urine
sample and new blood samples (1 clotted and 1
anticoagulated), drawn from a vein opposite the
infusion site, with the appropriate request form to
the blood transfusion center for investigation.
•Start a 24‐hour urine collection and record all
intake and output. Maintain fluid balance chart.
•

80. Investigating acute transfusion reactions
•Recordthe following information on the patient’s
notes:
–Type of transfusion reaction.
–Timelapse between start of transfusion and
when reaction occurred.
–Volume, type and bag number of blood
products transfused

81. •Immediately take post‐transfusion blood samples
(1 clotted and 1 anti‐coagulated) from the vein
opposite the transfusion site and forward to the
blood center for investigationof the following:
–Repeat ABO and RhDgroup.
–Repeat antibody screen and cross match.
–Full blood count.
–Coagulation screen.
–Direct antiglobulintest.
–Urea and creatinine.
–Electrolytes.

82. Acute Transfusion Reaction
•1-Haemolytic transfusion reaction
•2-Bacterial contamination and septic shock
•3-Transfusion Associated Circulatory
Overload
•4-Anaphylactic reaction
•5-Transfusion Related Acute Lung Injury

83. 1-Haemolytic transfusion reaction
•The most commoncause of reaction is ABO
incompatible transfusion. This almost always
arises
from:
-Errors in the blood request form.
-Taking blood from the wrong patient into a
pre‐labelledsample tube.
-Incorrect labellingof the blood sample tube
sent to the blood transfusion centre.
-Inadequate checking of the blood label against
the patient’s identity

84. •In the conscious patient, signs and symptoms
usually appear within minutes ofcommencing the
transfusion, sometimes when <10 mL blood has
been given.
•In an unconscious or anaesthetized patient,
hypotension and uncontrollable bleeding, from the
transfusion site, may be the only sign of an
incompatible transfusion

85. •Prevention:
•Correctly label blood sample and request form.
•Place the patient’s blood sample in the correct
sample tube.
•Always check the blood unit against the identity
of the patient at the bedside before transfusion.

86. •2-Bacterial contamination and septic shock
•Blood may become contaminated by:
-Bacteria from the donor’s skin entering the
blood unit during collection (usually staphylococci).
-Bacteraemiapresent in the blood of the donor
during collection (e.g. Yersinia).
-Improper handling during blood processing.
-Defect or damage to the blood bag.
-Thawing FFP or cryoprecipitate in a
water‐bath (often contaminated).

87. •Some contaminants, particularly Pseudomonas
species, grow at +2°C to +6°C and can survive or
multiply in refrigerated red cell units.
•Staphylococci grow in warmer conditions and
are able to proliferate in PCs which are stored at
+20°C to +24°C.

88. 3-Transfusion Associated Circulatory
Overload
•May occur when:
-Too much fluid is transfused.
-The transfusion is given too rapidly.
-Renal function is impaired.
Fluid overload is particularly likely to happen in
patients with:
-Chronic severe anemia.
-Underlying cardiovascular disease

89. 4-Anaphylactic reaction
1-rare complication of transfusion of blood
components or plasma derivatives.
2-The risk is increased by rapid infusion, typically
when fresh frozen plasma is used.
3-IgA deficiency in the recipient is a rare cause of
very severe anaphylaxis.
4-Cytokines in the plasma may occasionally cause
broncho‐constriction and vaso‐constriction in
recipients

90. •5-Occurs within minutes of starting the transfusion
and is characterized by:
-Cardiovascular collapse.
-Respiratory distress.
-No fever.
6-Fatal if it is not managed rapidly and aggressively

91. 5-Transfusion Related Acute Lung Injury
•caused by donor plasma that contains antibodies
against the recepiant’s leucocytes.
•Rapid failure of pulmonary function usually
presents within 1‐4 hours of starting transfusion,
with diffuse opacity on the chest X‐ray.
•There is no specific therapy. Intensive respiratory
and general support in an intensive care unit is
required.

92. •Delayed complications of
transfusion

93. •.1 Delayed haemolytic transfusion reaction.
•2 Post‐transfusion purpura.
•3-Transfusion associated graft‐versus‐host disease
(TA‐GVHD)
•4-Transfusion transmitted infections

94. 1 Delayed haemolytictransfusion
reaction.
•Signs appear 5‐10 days after transfusion:
•Fever.
•Anemia.
•Jaundice.
•Occasionally haemoglobinuria

95. 2 Post‐transfusion purpura
•This is a rare but potentially fatal complication of
transfusion of red cells or platelet concentrates,
caused by antibodies directed against platelet‐specific
antigens in the recipient.
•Most commonly seen in multigravida female
patients.
•Signs and symptoms:
•–Signs of bleeding.
•–Acute, severe thrombocytopenia 5‐10 days after
transfusion, defined as a platelet count of <100 x
109/L.

96. •Management:
•High dose corticosteroids.
•Give high dose IV immunoglobulin, 2 g/kg or 0.4
g/kg for 5 days.
•Plasma exchange.
•If available, give platelet concentrates that are
negativefor the platelet‐specific antigen against
which the antibodies are directed
•Recoveryof platelet count after 2‐4 weeks is usual.
•Unmatched platelet transfusion is generally
ineffective

97. 3-Transfusion associated
graft‐versus‐host disease (TA‐GVHD)
•Occurs in patients such as:
–Immuno‐deficient recipients of bone marrow
transplants.
-Immuno‐competent patients transfused with
blood from individuals with whom they have a
compatible HLA tissue type, usually blood relatives
particularly 1st degree.

98. Signs and symptoms typically occur 10‐12 days after
transfusion and are characterized by:
-Fever.
–Skin rash and desquamation.
–Diarrhoea.
–Hepatitis.
–Pancytopenia

99. Management
Treatment is supportive; there is no specific
therapy.
Prevention
Do not use 1st degree relatives as donors, unless
gamma irradiation of cellular blood components is
carried out to prevent the proliferation of transfused
lymphocytes.

100. 4-Transfusion transmitted infections
•HIV, Hepatitis B and C, syphilis, malaria.
•Cytomegalovirus (CMV).
•Other TTIs include human parvovirus ,B19,
brucellosis, Epstein‐Barr virus, toxoplasmosis,
Chagas disease, infectious mononucleosis and Lyme’s
disease.
Since a delayed transfusion reaction may occur days,
weeks or months after the transfusion, the association
with the transfusion may easily be overlooked